Jounce Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2017 to Q4 2022

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Jounce Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2017 to Q4 2022.
  • Jounce Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2022 was 17.5 %, a 62% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2022 17.5 +6.68 +62% Dec 31, 2022
Q3 2022 16.4 +5.06 +44.8% Sep 30, 2022
Q2 2022 14 +0.57 +4.26% Jun 30, 2022
Q1 2022 11.8 -4.93 -29.5% Mar 31, 2022
Q4 2021 10.8 -10.3 -48.9% Dec 31, 2021
Q3 2021 11.3 -10.9 -49% Sep 30, 2021
Q2 2021 13.4 -5.85 -30.4% Jun 30, 2021
Q1 2021 16.7 -15 -47.3% Mar 31, 2021
Q4 2020 21.1 -30.1 -58.8% Dec 31, 2020
Q3 2020 22.2 -52.9 -70.5% Sep 30, 2020
Q2 2020 19.2 -98.2 -83.6% Jun 30, 2020
Q1 2020 31.7 -91.2 -74.2% Mar 31, 2020
Q4 2019 51.2 -78.3 -60.5% Dec 31, 2019
Q3 2019 75.1 -41.6 -35.6% Sep 30, 2019
Q2 2019 117 +13.7 +13.2% Jun 30, 2019
Q1 2019 123 +28 +29.5% Mar 31, 2019
Q4 2018 129 +41.6 +47.3% Dec 31, 2018
Q3 2018 117 -31.5 -21.3% Sep 30, 2018
Q2 2018 104 Jun 30, 2018
Q1 2018 94.9 Mar 31, 2018
Q4 2017 87.8 Dec 31, 2017
Q3 2017 148 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.